Agenus Falls After $141M Zydus Deal Closes

Dow Jones

Jan 16

By Katherine Hamilton

Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences.

Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months.

Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash.

The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece.

Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders.

Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 15, 2026 13:29 ET (18:29 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603980629"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603980629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603980629?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 02:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603980629","market":"fut","top_or_hot":-1,"title":"Agenus Falls After $141M Zydus Deal Closes","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n</p>\n<p>\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n</p>\n<p>\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n</p>\n<p>\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n</p>\n<p>\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n</p>\n<p>\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2026 13:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Falls After $141M Zydus Deal Closes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Falls After $141M Zydus Deal Closes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-16 02:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n</p>\n<p>\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n</p>\n<p>\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n</p>\n<p>\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n</p>\n<p>\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n</p>\n<p>\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 15, 2026 13:29 ET (18:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603980629","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603980629","pubTimestamp":1768501740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences.Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months.Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash.The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece.Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders.Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGEN":"艾吉纳斯公司"},"translate_title":"1.41亿美元Zydus交易完成后Agenus股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Agenus slipped after the oncology company closed a $141 million deal with Zydus Lifesciences. \n\n\n  Agenus stock slid 20%, to $3.73, midday Thursday. Shares are down 6.9% over the past three months. \n\n\n  Through the deal, which was first announced in June 2025, the Lexington, Mass., company sold two of its biologics manufacturing facilities in California to Zydus for $75 million in cash. \n\n\n  The Indian company also made a $16 million equity investment in Agenus, which amounts to 2.1 million shares at $7.50 apiece. \n\n\n  Zydus also plans to make payments of up to $50 million contingent on milestones of BOT and BAL production orders. \n\n\n  Agenus is giving Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka. Agenus would be eligible to receive a 5% royalty on net sales in those countries. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 15, 2026 13:29 ET (18:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}